Evidence first
Human trial findings are separated from hypotheses and unknowns.
Device shown for design context
InvestigationalLY3437943 · triple receptor agonist
Metabolic research
Retatrutide
A closer look at triple-receptor metabolic science.
Retatrutide is an investigational medicine being studied for obesity and related metabolic conditions. It activates GIP, GLP-1 and glucagon receptors. The research is notable, but the medicine is not approved for routine clinical use and long-term benefit–risk remains under evaluation.
Not approved for routine clinical use by major medicines regulators at the time of writing. Trial participation, prescribing and supply rules vary by region and must be verified by a qualified clinician.
01 · The proposition
Promising research, presented without the promises.
This page distinguishes observed human evidence from biological rationale and what remains unknown.
Clinician assessed
Suitability requires individual medical review, not a product quiz alone.
Bloodwork informed
Baseline markers can help establish context and monitoring needs.
02 · Areas under study
What researchers are measuring.
Body weight
Substantial mean weight reductions were reported in a phase 2 obesity trial.
Trial averages are not personal predictions; phase 3 confirmation and longer follow-up are ongoing.
Metabolic markers
Studies have reported changes across several cardiometabolic measures alongside weight change.
The clinical meaning depends on baseline health, concurrent care and individual response.
Appetite and energy balance
The three-receptor mechanism is designed to influence appetite, nutrient signalling and energy expenditure.
Mechanism does not guarantee an outcome, and effects can differ materially between people.
03 · How it is being studied
Three signals. One investigational molecule.
The mechanism is biologically plausible, but receptor activity alone cannot predict an individual clinical result.
GIP
Nutrient signalling
GIP receptor activity is being studied for its role in insulin response, energy storage and metabolic coordination.
GLP-1
Satiety and glucose regulation
GLP-1 receptor activity can influence appetite, gastric emptying and glucose-dependent insulin signalling.
Glucagon
Energy mobilisation
Glucagon receptor activity may increase energy expenditure while also requiring careful metabolic and hepatic assessment.
A discussion may be relevant when
- Adults discussing evidence-based weight or metabolic care with a qualified clinician
- People prepared for baseline assessment, ongoing monitoring and lifestyle support
- Those who understand that published trial outcomes do not predict an individual result
Not a route to self-treatment
- Anyone seeking unsupervised or research-chemical access
- People who are pregnant, planning pregnancy or breastfeeding
- People with relevant endocrine, gastrointestinal or medication risks unless specifically cleared by their clinician
04 · Safety
What is known—and what is not yet established.
Retatrutide has no established routine-use safety profile. Trial reports describe a class-consistent pattern of gastrointestinal effects, while uncommon and long-term risks remain under investigation.
Reported commonly
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Reduced appetite
Seek urgent medical help
- Severe or persistent abdominal pain
- Signs of dehydration or inability to keep fluids down
- Symptoms of a serious allergic reaction
- Any sudden or concerning change after exposure
Clinical monitoring context
- Weight and nutrition status
- Glucose regulation
- Kidney and liver context
- Medication interactions
- Adverse effects and tolerability
05 · Evidence ladder
Confidence should match the evidence.
Human evidence
Phase 2 obesity trial
A randomised phase 2 trial reported dose-dependent weight reduction over 48 weeks, with gastrointestinal adverse events most common during escalation.
Confirmation underway
TRIUMPH phase 3 programme
Multiple phase 3 studies are evaluating efficacy and safety across obesity and related conditions. Full programme results are not yet available.
Mechanistic rationale
Triple agonism
Early clinical and preclinical work supports the biological rationale for combining GIP, GLP-1 and glucagon receptor activity.
Not established
Routine clinical use
Approved indications, standard prescribing information, broad population safety and long-term outcomes have not been established.
06 · Bloodwork bridge
Understand the baseline before discussing an intervention.
Bloodwork cannot determine suitability on its own. It can help a clinician understand metabolic context, identify issues needing attention and choose an appropriate monitoring plan.
HbA1c and fasting glucoseLipidsLiver markersKidney functionThyroid context where clinically relevant
Upload existing bloodwork 
07 · Practitioner pathway
The product page is not the decision.
A safe decision starts with context and remains reviewable over time.
Build your health baseline
Start with your goals, medical history, current medicines and available bloodwork.
Qualified clinical review
A practitioner assesses contraindications, evidence, alternatives and local availability.
Shared decision
If any treatment is appropriate, the clinician explains expected benefits, uncertainties and monitoring.
Ongoing review
Symptoms, adherence, relevant measurements and follow-up testing inform each next decision.
08 · FAQ
Questions worth asking.
Retatrutide remains investigational and is not approved for routine clinical use by major medicines regulators at the time of writing. Regulatory status and lawful access can change and vary by country, so a qualified clinician must verify the current position locally.
09 · Continue exploring
Related research.
Sources and access
Read the source, then discuss the context.
Secondary access action
Subject to clinical controls
Adding an item does not confirm suitability, prescribing, availability or supply. Existing clinical review and checkout controls still apply.
A$449
Medical information only. This page does not diagnose, prescribe or recommend treatment. Retatrutide is investigational; outcomes, risks, lawful access and regulatory status vary. Seek urgent medical care for serious symptoms.